Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials

  title={Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials},
  author={Antonio Simone Lagan{\`a} and Amerigo Vitagliano and Marco Noventa and Guido Ambrosini and Rosario D'Anna},
  journal={Archives of Gynecology and Obstetrics},
PurposeTo evaluate whether oral myo-inositol supplementation (MI) is able to reduce the amount of gonadotropins (GA) and the length of controlled ovarian hyperstimulation (SL) in both Polycystic Ovarian Syndrome (PCOS) and non-PCOS women undergoing in vitro fertilization (IVF).MethodsWe performed a systematic review (PROSPERO ID: CRD42017069439) of randomized controlled trials (RCTs). We searched articles published in English between January 1985 to August 2017, using the combination of the… 

Myo-Inositol’s Role in Assisted Reproductive Technology: Evidence for Improving the Quality of Oocytes and Embryos in Patients With Polycystic Ovary Syndrome

There is a lack of statistically significant evidence to support the use of MI in enhancing the quality of oocyte and/or embryo in PCOS; however, many of the reviewed studies have shown a trend toward the improvement of embryo quality in women with PCOS after MI supplementation.

Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach

Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies

Myo-inositol is effective in normalizing ovarian function, improving oocyte and embryo quality in PCOS, however further evaluations by large multicentre randomized controlled trials are needed to assess the clinical pregnancy and live birth rates in ART.

An innovative approach to polycystic ovary syndrome

The main stages of Vittorio Unfer’s scientific career have been closely intertwined with important phases of the recent pharmacological research about the topic and his researches allowed to identify “the D-Chiro-Inositol Paradox in the Ovary” and the best myo- inositol/D-chiro-inositol ratio (40:1) for the treatment of PCOS.

Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary

It is quite surprising to find that inositol-based treatments for PCOS seem to be randomly chosen and are often combined with useless or even counterproductive molecules, all of which can weaken myo-inositol's efficacy.

Inositols in Polycystic Ovary Syndrome: An Overview on the Advances

Laparoscopic Ovarian Drilling Reduces Testosterone and Luteinizing Hormone/Follicle-Stimulating Hormone Ratio and Improves Clinical Outcome in Women with Polycystic Ovary Syndrome

LOD significantly reduced testosterone and LH/FSH ratio in ovulatory and conceived groups, and the menstrual cycle became regular, and hirsutism and acne were reduced after LOD in women with PCOS.

Advances in non-hormonal pharmacotherapy for the treatment of male infertility: the role of inositols

Both myo-inositol and DCI are found to ameliorate sperm motility and MMP in vitro and should be preferred in patients with idiopathic asthenozoospermia, especially in case of impaired sperm mitochondrial function.

Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome

The association of d-chiro-inositol and alpha lipoic acid improves menstrual cycle length, restoring ovulation in the majority of women, and insulin sensitivity improved in women with IR only, confirming that in presence of IR the d- Chiro inositol has a role in restoring the insulin action overcoming the inactivity of epimerase.



Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome

Myo-Inositol and melatonin proved to be efficient predictors for positive IVF outcomes, correlating with high oocyte quality, and routinely MI and M supplementation in the IVF protocols was integrated.

Effects of myo-inositol supplementation on oocyte's quality in PCOS patients: a double blind trial.

It is suggested that myoinositol may be useful in the treatment of PCOS patients undergoing ovulation induction, both for its insulin-sensitizing activity, and its role in oocyte maturation.

Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.

The data show that, in PCOS patients having a normal insulin response, myo- inositol treatment rather than D-chiro-inositol is able to improve oocyte and embryo quality during ovarian stimulation protocols.

Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study

The findings suggest that the addition of myo-inositol to folic acid in non PCOS-patients undergoing multiple follicular stimulation for in-vitro fertilization may reduce the numbers of mature oocytes and the dosage of rFSH whilst maintaining clinical pregnancy rate.

Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials

An overview on the clinical outcomes of the MYO use as a treatment to improve ovarian function and metabolic and hormonal parameters in women with PCOS is provided.

Myo-inositol therapy for poor-responders during IVF: a prospective controlled observational trial

The results suggest that MI therapy in poor responders results in an increased of the number of oocytes recovered in MII and of the Gonadotropin Ovarian Sensitivity Index (OSI), suggesting a MI role in improving ovarian response to gonadotropins.

Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET

Myoinositol supplement increase clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET, and may improve the quality of embryos, and reduce the unsuitable oocytes and required amount of stimulation drugs.

Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study

  • P. ArtiniO. M. Di Berardino V. Cela
  • Medicine, Biology
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2013
Myo-inositol administration improves reproductive axis functioning in PCOS patients reducing the hyperinsulinemic state that affects LH secretion, and insulin sensitivity, expressed as glucose-to-insulin ratio and HOMA index resulted significantly improved after 12 weeks of treatment.